- Home
- TLN vs DGX Comparison
TLN vs DGX Comparison
Compare TLN & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLN
- DGX
- Stock Information
- Founded
- TLN 2015
- DGX 1967
- Country
- TLN United States
- DGX United States
- Employees
- TLN N/A
- DGX N/A
- Industry
- TLN Electric Utilities: Central
- DGX Medical Specialities
- Sector
- TLN Utilities
- DGX Health Care
- Exchange
- TLN Nasdaq
- DGX Nasdaq
- Market Cap
- TLN 18.4B
- DGX 20.5B
- IPO Year
- TLN N/A
- DGX 1996
- Fundamental
- Price
- TLN $408.09
- DGX $182.30
- Analyst Decision
- TLN Strong Buy
- DGX Buy
- Analyst Count
- TLN 13
- DGX 15
- Target Price
- TLN $349.23
- DGX $185.40
- AVG Volume (30 Days)
- TLN 1.1M
- DGX 672.5K
- Earning Date
- TLN 11-13-2025
- DGX 10-21-2025
- Dividend Yield
- TLN N/A
- DGX 1.76%
- EPS Growth
- TLN N/A
- DGX 12.66
- EPS
- TLN 3.80
- DGX 8.35
- Revenue
- TLN $2,128,000,000.00
- DGX $10,522,000,000.00
- Revenue This Year
- TLN $16.21
- DGX $11.13
- Revenue Next Year
- TLN $55.42
- DGX $3.41
- P/E Ratio
- TLN $107.36
- DGX $21.81
- Revenue Growth
- TLN 1.09
- DGX 12.58
- 52 Week Low
- TLN $148.02
- DGX $146.17
- 52 Week High
- TLN $413.00
- DGX $185.62
- Technical
- Relative Strength Index (RSI)
- TLN 69.02
- DGX 55.51
- Support Level
- TLN $397.91
- DGX $179.66
- Resistance Level
- TLN $410.00
- DGX $185.05
- Average True Range (ATR)
- TLN 12.63
- DGX 2.68
- MACD
- TLN 1.12
- DGX -0.26
- Stochastic Oscillator
- TLN 90.17
- DGX 65.67
About TLN Talen Energy Corporation Common Stock
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.